Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Mark Morris Davis · STANFORD UNIVERSITY · 2024 · $187,843 — PROJECT 3: SUMMARY COVID-19 is currently a global pandemic, but human T cell responses contributing to the quantity and quality of SARS-CoV-2 specific antibodies, or acting by cytotoxic mechanisms on infected cells, remain poorly understood. In this U54 Project, we will study virus-specific T cell i…
Amy R. Kontorovich · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $211,250 — PROJECT SUMMARY The cardiac inflammatory disorder myocarditis is a rare but important complication following vaccination against COVID-19. Other than younger age and male sex, no risk factors for this adverse outcome have been found. Recognition of host factors that predispose to vaccine-associated …
Chang Liu · JOHNS HOPKINS UNIVERSITY · 2024 · $489,658 — PROJECT SUMMARY/ABSTRACT Over the last two decades, three highly pathogenic human coronaviruses, including SARS-CoV-2, have emerged, arguing that future deadly pandemics of new or re-emerging coronaviruses and other RNA viruses are almost inevitable. The urgent need to treat these fatal infectious …
Rongsheng Jin · TUFTS UNIVERSITY BOSTON · 2024 · $802,815 — ABSTRACT In previous NIH sponsored research we successfully tested the hypothesis that integrating structural and mechanistic information into heteromultimeric VHH-based neutralizing agent (VNA) design facilitated development of antitoxins with even greater efficacy and versatility. In this renewal …
Ralph S Baric · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $748,081 — The 21st century has recorded the emergence of three highly pathogenic respiratory coronaviruses, including Severe Acute Respiratory Coronavirus (SARS-CoV) in 2003, the ongoing Middle East Respiratory Coronavirus (MERS-CoV) in 2013 and a novel SARS-like coronaviruses SARS-CoV2 (SARS2) in Wuhan, Chin…
Francesca-Fang Liao · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2024 · $657,612 — Abstract White matter (WM) damage has increasingly been recognized as an important contributing factor to neurodegeneration and dementia, however, little is known of the specific molecular and cellular events underlying the pathogenesis. Clinically, chronic hypoperfusion is often associated with WM …
Jane R Taylor · YALE UNIVERSITY · 2024 · $330,750 — Drug-associated conditioned stimuli (CS), or cues, contribute to both the progression and persistence of addiction. We hypothesize, as have others, that blocking reconsolidation of cocaine-cue memories could prevent cue-induced relapse. Reconsolidation is a process whereby reactivation of a memory r…
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2024 · $2,356,969 — SUMMARY – OVERALL While there is an urgent need for vaccines eliciting broadly neutralizing antibodies (bnAbs) against the highly mutable HIV-1 retrovirus to stem its global spread, this goal remains elusive. Antibodies produced against trimeric gp160 sites of vulnerability during natural infection…
Melody Y Zeng · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $651,485 — Abnormal and potentially life-threatening blood clotting is seen in other severe infections, such as SARS- CoV-2, MERS, and H1N1 influenza. Platelets are produced by megakaryocytes. Enhanced megakaryopoiesis is found in severe COVID-19. Increased megakaryopoiesis is commonly found in autoimmune dise…
Hao Wu · BOSTON CHILDREN'S HOSPITAL · 2024 · $542,900 — Summary A nanobody that recognizes immunoglobulin light chains, conjugated to a molecular entity that recognizes a virus-infected or a cancerous cell, is an effective therapeutic: A single injection of fusion constructs comprising an anti-kappa light chain nanobody (VHHkappa) and zanamivir, a small …
Betsy C. Herold · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $603,661 — There are no effective vaccines or monoclonal antibodies available for the prevention or treatment of herpes simplex viral infections. This application addresses this global public health priority. We developed a novel single-cycle vaccine strain deleted in glycoprotein D (gD), designated DgD-2. DgD…
TOMAS KIRCHHAUSEN · WASHINGTON UNIVERSITY · 2024 · $752,346 — The long term goal of this study is to understand how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), enters cells and how to block that process through the use of therapeutics. Like other enveloped viruses, SARS-CoV-2 cell entry…
James J Kobie · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2024 · $841,341 — PROJECT SUMMARY SARS-CoV-2 has infected over 138 million people and resulted in over 2.8 million deaths so far, with the expectation the pandemic will continue for many more months, and the virus will persist endemically for years, exacerbated by emerging variants of concern (VoC). Although several …
Goran Bajic · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $780,825 — Immunodominance, the observation that epitopes on an antigen are not “born equal”, poses a major challenge for next-generation vaccines against rapidly evolving pathogens. An underlying premise of this proposal is that in order to engage in rational immunogen design for next-generation vaccines, we …
Jalees Rehman · UNIVERSITY OF ILLINOIS AT CHICAGO · 2024 · $724,225 — PROJECT SUMMARY / ABSTRACT Coronavirus disease 2019 (COVID-19) is a devastating systemic inflammatory syndrome caused by the coronavirus SARS-CoV-2 which has resulted in over 500,000 deaths in the US during the past year, with this high rate of mortality being attributed in large part to the develop…
STEPHEN COPLAN HARRISON · BOSTON CHILDREN'S HOSPITAL · 2024 · $399,356 — Summary The structure of a virus particle must conform to the mechanism by which it enters and infects a cell. We seek to relate structures of virus particles and viral surface proteins to mechanisms of the steps in cell attachment, uptake and penetration that initiate a productive infection. The pr…
Eric M. Poeschla · VA EASTERN COLORADO HEALTH CARE SYSTEM · 2024 — SARS-CoV-2 emerged in late 2019, with much evidence tracing the initial human spillover to a market with extensive human-animal contact. As the coronavirus spread in its new host species, multiple variants of concern representing distinct genetic lineages appeared and propagated globally. Ongoing vi…
Michael R. Farzan · BOSTON CHILDREN'S HOSPITAL · 2024 · $221,250 — Abstract The central hypothesis of this proposal is that the efficacy of mRNA vaccines that deliver membrane-anchored immunogens can be improved by localizing the immunogen to extracellular vesicles (EVs, small membrane- limited structures shed by eukaryotic cells). Our rationale is that EVs provide…
Kyuyeon Han · UNIVERSITY OF ILLINOIS AT CHICAGO · 2024 · $239,850 — Project Summary/Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could behave similar to the influenza virus, re- emerging every year in slightly different forms. More importantly, SARS-CoV-2 keeps making various mutants with higher infection rates than previous ones. The spike …
Andrew Ouellette · JACKSON LABORATORY · 2024 · $34,077 — PROJECT SUMMARY To date, there is a significant knowledge gap surrounding the genetic and neuronal mechanisms that regulate cognitive resilience to Alzheimer’s Disease (AD). Without a better understanding of these mechanisms, developing therapeutics to enhance cognitive longevity in the face of AD w…